RxDoctor Payments Data

Mouhammed Sheikha, MD

Internal Medicine · Blue Island, ILNPI 1619986387

Payments from drug & device makers

$1,465in general payments, 2019–2025

Across 71 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$262
  • Novo Nordisk$251
  • AbbVie$167
  • Johnson & Johnson$92
  • Otsuka America Pharmaceutical, Inc.$87
  • GSK$82
  • plus $523 from 15 others

What the payments were for

  • Food & beverage$1,40396%
  • Education$624%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,465 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$98,521
Medicare patients
336
Services billed
2,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide136$210,419
OzempicSemaglutide121$167,003
EliquisApixaban125$147,440
MounjaroTirzepatide78$113,782
JardianceEmpagliflozin67$89,681
FarxigaDapagliflozin Propanediol38$37,526
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$30,073
RexultiBrexpiprazole13$26,902
Breo ElliptaFluticasone/Vilanterol27$20,266
XareltoRivaroxaban16$20,124
Humulin R U-500 KwikpenInsulin Regular, Human21$18,433
Tresiba Flextouch U-200Insulin Degludec15$18,288
Aripiprazole23$17,263
MyrbetriqMirabegron13$13,311
Atorvastatin Calcium913$9,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$262$324,201214 claims
Novo NordiskOzempic$251$167,003121 claims
PfizerEliquis$72$147,440125 claims
Boehringer IngelheimJardiance$18$89,68167 claims
GSKTrelegy Ellipta, Breo Ellipta$82$50,33959 claims
AstraZenecaFarxiga$11$37,52638 claims
Otsuka America Pharmaceutical, Inc.Rexulti$87$26,90213 claims
Johnson & JohnsonXarelto$92$20,12416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Blue Island

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →